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Estrogen Receptor- Prevents Cardiac Fibrosis
Ali Pedram, Mahnaz Razandi, Fiona O’Mahony, Dennis Lubahn, and Ellis R. Levin
Division of Endocrinology (M.R., E.R.L.), Department of Veterans Affairs Medical Center, Long Beach,
California 90822; Departments of Medicine (A.P., E.R.L.), Biochemistry (E.R.L.), and Pharmacology
(E.R.L.), University of California, Irvine, Irvine, California 92717; Department of Molecular Medicine
(F.O.), Royal College of Surgeons in Ireland, Dublin 9, Ireland; and Department of Biochemistry (D.L.),
University of Missouri, Columbia, Missouri 65211
Development of cardiac fibrosis portends the transition and deterioration from hypertrophy to
dilation and heart failure. Here we examined how estrogen blocks this important development.
Angiotensin II (AngII) and endothelin-1 induce cardiac hypertrophy and fibrosis in humans. and
we find that these agents directly stimulate the transition of the cardiac fibroblast to a myofibro-
blast. AngII and endothelin-1 stimulated TGF1 synthesis in the fibroblast, an inducer of fibrosis
that signaled via c-jun kinase to Sma- and Mad-related protein 3 phosphorylation and nuclear
translocation in myofibroblasts. As a result, mesenchymal proteins fibronectin and vimentin were
produced, as were collagens I and III, the major forms found in fibrotic hearts. 17-Estradiol (E2)
or dipropylnitrile, an estrogen receptor (ER) agonist, comparably blocked all these events, re-
versed by estrogen receptor (ER) small interfering RNA. E2 and dipropylnitrile signaling through
cAMP and protein kinase A prevented myofibroblast formation and blocked activation of c-jun
kinase and important events of fibrosis. In the hearts of ovariectomized female mice, cardiac
hypertrophy and fibrosis were induced by AngII infusion and prevented by E2 administration to
wild type but not ER knockout rodents. Our results establish the cardiac fibroblast as an impor-
tant target for hypertrophic/fibrosis-inducing peptides the actions of which were mitigated by
E2/ER acting in these stromal cells. (Molecular Endocrinology 24: 0000–0000, 2010)
The role of estrogen in preventing heart disease inwomen has been controversial. Many retrospective
studies showed that 17-estradiol (E2) or other estrogens
decreased the incidence of myocardial infarction (MI) by
approximately 45% (1–3). However, the initial analysis
from prospective trials such as the Women’s Health Ini-
tiative did not support this conclusion. Rather, the Wom-
en’s Health Initiative results indicated no protective
effects of estrogen in older women taking hormone re-
placement therapy (HRT) initiated at a mean of approx-
imately 15 yr after the menopause, and a slight increase in
MI or stroke (4, 5). Reevaluation of these data for women
commencing HRT within 10 yr of the menopause indi-
cated a 36% decrease in the rate of MI, compared with
women not taking HRT (6, 7). Furthermore, these same
women had a strong decrease in the coronary artery cal-
cium score, an indicator of arterial disease (8). Thus, the
timing in initiating HRT after the menopause seems to be
important in preventing cardiovascular diseases.
Regarding the outcomes of heart and vascular disease,
the most common cause of death in humans is cardiac
failure. This often occurs after repeated ischemia (com-
promised coronary artery blood flow) or after poorly con-
trolled hypertension. Hypertension leads to increased ar-
terial vascular resistance, resulting in cardiomyocyte
hypertrophy (9). If the underlying cause is not controlled,
cardiac hypertrophy progresses to dilation, apoptotic
thinning of myocytes, and ultimately heart failure (10).
Estrogen may defend against the impetus for these events
in several ways, because genetic deletion of estrogen re-
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ceptor (ER) results in hypertension
developing in both female and male
mice (11). Furthermore, estrogen defi-
ciency in hypertensive rats results in en-
dothelial dysfunction and oxidative
stress (12).
Estrogen may also directly mitigate
the development of cardiac hypertrophy
as supported in various animal models
(13). Mice deficient for the FKBP12.6
protein have abnormal sarcoplasmic re-
ticulum calcium regulation, due to ab-
normal control of the cardiomyocyte ry-
anodine receptor. This leads to profound
cardiac hypertrophy and failure in the
male mice (14). Interestingly, postnatal
female mice do not develop cardiac hy-
pertrophy unless administered tamox-
ifen, indicating ER protection. Several
groups have implicated E2 and ER in
preventing hypertrophy due to a variety
of stimuli inmice (15, 16). Jazbutyte et al.
(17) showed that administration of
an ER-specific agonist, 8-VE2 (Le-
verkusen, Germany, Bayer Pharmaceu-
tical), to ovariectomized spontaneously
hypertensive rats lowers systolic blood
pressure and peripheral arterial resis-
tance, and attenuates cardiac hyper-
trophy. Thus, the overall effects of E2
on the myocardium are probably
both indirect and direct.
There is a large literature implic-
ating abnormal activity of the calc-
ium-sensitive phosphatase, calcineurin
(PP2B) in cardiac hypertrophy. Cal-
cineurin activity is increased by a vari-
ety of hypertrophic stimuli, including
angiotensin (18). Calcineurin activa-
tion dephosphorylates serine residues
of nuclear factor of activated T-lym-
phocytes transcription factors, leading
to their nuclear translocation and sub-
sequent up-regulation of genes that
mediate cardiac hypertrophy (19).
Calcineurin also activates myocyte-
enhancing factor-2, up-regulating hy-
pertrophic genes. We recently pub-
lished a novel down-regulation of
calcineurin activity by estrogen, medi-
ated through stimulation of MCIP1
FIG. 1. Regulation of the conversion of cardiac fibroblasts to myofibroblasts. A,
Hypertrophic factors cause the transition of fibroblasts to myofibroblasts, prevented by E2 or
DPN. AngII or ET-1 (100 nM) was incubated with fibroblasts for 24 h. Expression of -SMA
(white arrows) is a marker of myofibroblasts. B, Distribution of ER and ER in cardiac
fibroblasts. Left, freshly isolated neonatal rat cardiac fibroblasts were acutely cultured without
or with AngII for 24 h, the cells were lysed, and membrane, cytoplasmic, and nuclear
fractions were isolated by differential centrifugation for Western blotting, as per Materials
and Methods. The study was repeated. Purity of the cell fractions was demonstrated by
immunoblotting with antibodies to 5-NT, an integral plasma membrane protein, transportin
and NF T2, nuclear proteins, and -coatomer protein complex, subunit beta 2 (Golgi) and
cytochrome c (mitochondria) cytosolic proteins. Nonspecific IgG antibodies showed no
staining, and ER antibodies first preabsorbed with specific ER isoform proteins also produced
no ER detection (data not shown). Right, specificity of ER isoform siRNA. Transfection of
fibroblasts with either control siRNA or siRNA to ER or ER was performed, and the cells
then lysed at 48 h for immunoblotting with either ER or ER antibody. ER or ER antibody
does not detect the other isoform: Fibroblasts were lysed, and lysate was immunoprecipitated
with each ER isoform antibody and then blotted with each ER isoform antibody. C,
Quantification of myofibroblasts in response to AngII or ET-1, significantly prevented by 10
nM E2 or DPN, but not PPT. The bar graph was from three experiments combined. *, P 
0.05 by ANOVA plus Schefe’s test for control vs. AngII, ET-1, or with PPT. , P  0.05 for
AngII or ET-1 vs. same plus E2 or DPN. D, siRNA knockdown of ER reverses the effects of E2
or DPN to prevent myofibroblast formation. Three experiments were combined for bar graph
data. *, P  0.05 for control vs. AngII or AngII  E2 or DPN  ERsiRNA. , P  0.05 for
AngII vs. same  E2 or DPN without or with siRNA to ER. E, EGF- or PDGF-induced
myofibroblast formation is inhibited by E2 or DPN. Experimental procedures and data analysis
were similar to panel C. IP, Immunoprecipitation.
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gene transcription, preventing cardiomyocyte hypertro-
phy in vitro (20) and in vivo (13). This could account for
the ability of E2 to dampen the downstream effects of cal-
cium dysregulation in female mice, a defect that induces
cardiac hypertrophy in male mice (14). Regarding human
cardiac hypertrophy, hormone replacement lowers vascular
resistance and decreases left ventricular hypertrophy in hy-
pertensive, postmenopausal women (21).
A very important event in the progression of cardiac
hypertrophy to heart dilation and failure is progressive
fibrosis of the heart (22, 23). This occurs in both the
interstitial and perivascular spaces of the myocardium.
Hypertrophic agents such as angiotensin II (AngII)
and endothelin 1 (ET-1) are produced in fibroblasts
and macrophages, as well as the endothelium. AngII
and ET-1 promote fibrosis in part by inducing TGF1
production resulting in downstream signaling from
TGF1 receptors (24). These events occur upon tran-
sition of the cardiac fibroblast to a myofibroblast phe-
notype, the latter synthesizing procollagens I and III
(24, 25). We previously determined that AngII-induced
cardiac hypertrophy was associated with cardiac fibro-
sis, and E2 inhibited this by unclear mechanisms (13).
Recent studies in a chronic model of neurohormonal-
induced heart failure also showed reduction of cardiac
hypertrophy and fibrosis by estrogen, through undeter-
mined mechanisms (26). We therefore sought to under-
stand the target cell and the cellular
and molecular mechanisms by which
E2 inhibited this important event in
the progression of cardiac disease.
Results
Estrogen and ER prevent
fibroblast to myofibroblast
transition
When fibroblasts undergo the transi-
tion to myofibroblasts, this bestows the
capability of producing collagen and
other proteins that cause fibrosis (22,
23). Whether estrogen modulates this
transition is unknown. We first deter-
mined that the well-recognized cardiac
hypertrophic factors AngII and ET-1
(27) directly cause the fibroblast-to-myo-
fibroblast transition in many cells, seen
as a change in the morphology of fibro-
blasts to a more rounded, muscle-like
phenotype (Fig. 1A). These cells also
strongly expressed -smooth muscle ac-
tin (SMA), an important marker of the
myofibroblast that is barely expressed in fibroblasts (28).
Importantly, 10 nM E2 markedly down-regulated -SMA
expression and caused as much as a 75% decrease in the
number of phenotypic myofibroblasts seen from coculture
of the sex steroid with AngII or ET-1 (also see Fig. 1C). The
ER agonist dipropylnitrile (DPN) comparably prevented
myofibroblast transition, indicating thatE2probablyblocks
stimulation of myofibroblast development through ER.
We then found that fibroblasts (no AngII exposure)
and myofibroblasts (incubated with AngII) contain com-
parable amounts and a similar distribution of ER and
ER located in the nucleus, cytoplasm, and plasma mem-
brane (Fig. 1B, left). Interestingly, ER was more abun-
dant in extranuclear locations (cytoplasm and plasma
membrane fractions) whereas ER localization was pre-
dominantly nuclear. Purity of the cell fractions was
shown through immunoblotting the fractions for mem-
brane [5-neurotropin (NT), nuclear (transportin and NT
F2), and cytoplasmic (-coatomer protein complex, sub-
unit beta 2 and cytochrome c) proteins, and small inter-
fering RNA (siRNA) and antibody specificity is shown
also (Fig. 1B, right). Thus, these cells could directly me-
diate the actions of E2 at either ER isoform present in
several cellular pools.
To further investigate this, we compared and quan-
tified the effects of E2, the ER agonist, propyl-pyra-
FIG. 1. (Continued).
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zole-triol (PPT), and DPN, each at 10 nM. AngII and
ET-1 caused a near 6-fold increase in myofibroblasts
compared with control conditions (Fig. 1C). Only DPN
and E2 caused a significant and equivalent inhibition of
the fibroblast transition. Further supporting the idea
that ER mediates these effects of E2, we knocked
down ER or ER expression with siRNA for 48 h, as
previously described (29). AngII-stimulated transition
to myofibroblasts was inhibited equipotently by E2 or
DPN; these effects were only reversed by ER (but not
ER) siRNA (Fig. 1D).
It has also been reported that epidermal growth factor
(EGF) and platelet-derived growth factor (PDGF) con-
tribute to the development of cardiac hypertrophy (30,
31), but it is not established that they directly promote
fibrosis. Here we found that each hypertrophic factor
induced the fibroblast transition to myofibroblast, again
blocked by E2 andDPN (Fig. 1E). In summary, important
cardiac hypertrophic factors directly stimulate myofibro-
blast formation, prevented by E2 and ER.
Fibrosis-inducing proteins are inhibited
by estrogen
Initially, stimulated fibroblasts produce various pro-
teins that induce the transition to myofibroblasts in an
autocrine fashion. The latter cells then produce additional
proteins that importantly contribute to fibrosis. We first
determined the modulation of the TGF1 protein. This
growth factor is an important stimulator of fibroblast
transition and signals to the production of fibrosis-pro-
FIG. 2. Production of proteins from the myofibroblast that contribute to fibrosis. A, TGF1 production in fibroblasts. Cardiac fibroblasts were
incubated with 100 nM AngII or ET-1  10 nM E2 or DPN for 6 or 24 h. TGF1 was immunoprecipitated from the lysed cells, and separation by
SDS-PAGE preceded protein transfer to nylon membranes for immunoblotting. -Actin protein is shown as a control and loading protein. The bar
graph is three experiments combined. *, P  0.05 for control vs. hypertrophic factors; , P  0.05 for hypertrophic proteins vs. same plus E2 or
DPN. B–D, -Smooth muscle actin, fibronectin, and vimentin protein expression, respectively, in fibroblasts. The experiments were similar to panel
A. The bar graphs reflect three combined experiments. Data analysis was the same as in Fig. 1C. E, Collagen I and III formation in fibroblasts. Cells
were placed in methionine-free media for 1 h, [35S]methionine was then added for 2 h, and cells were incubated with peptides  steroids for
24 h, at which time new protein synthesis was determined. The bar graph represents data from three experiments. *, P  0.05 for control vs.
AngII or ET-1. , P  0.05 for AngII or ET-1 vs. same  E2 or DPN.
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ducing proteins in both autocrine and paracrine fashions
(24, 25).We found that AngII and ET-1 each significantly
stimulated TGF1 protein production in cardiac fibro-
blasts at both 6 and 24 h, significantly inhibited by E2 or
DPN (Fig. 2A). We also found that -SMA, fibronectin,
and vimentin proteins each were stimulated by the hyper-
trophic factors, inhibited by E2 or DPN (and not by PPT)
(Fig. 2, B–D). Collagens I and III have been strongly im-
plicated as the major proteins that constitute cardiac fi-
brosis in disease models (32). AngII or ET-1 induced both
collagens, inhibited by E2 or DPN (Fig. 2E). These studies
indicate that key proteins implicated in the fibroblast tran-
sition and the production of fibrosis are stimulated by hy-
pertrophic factors but inhibited by estrogen acting at ER.
Modulation of SMAD (Sma- and Mad-related
protein) transcription factors
Signaling to fibrosis has been reported to occur
through several pathways directly enacted by TGF1 in
particular (24) and applicable to AngII and ET-1 actions.
Upon stimulation of the fibroblast with hypertrophic
agents, TGF1 is produced and secreted, binding its Type
II receptor (a serine/threonine kinase) that recruits and
phosphorylates/activates the Type I TGF receptor. As a
result, SMAD2 and 3 proteins are recruited to, then phos-
phorylated and activated by, the Type I receptor (25, 33).
Phosphorylation ultimately releases SMAD 2 and 3 pro-
teins from the receptor to sometimes complex with
SMAD 4 (cell specific) and translocate to the nucleus. In
the nucleus, SMADs 2 and 3 collaborate with other tran-
scription factors to induce gene transcription important
to fibrosis.
We therefore determined phosphorylation of SMAD 3
and its cellular localization. We used phospho-Ser423/435
antibodydirected against the activating phosphorylations of
SS (serine-serine) amino acids in the SSXS sequence. AngII
and ET-1 stimulated SMAD3 phosphorylation and nu-
clear localization (Fig. 3A). Both aspects were inhibited
FIG. 3. E2 and ER prevent signaling to fibrosis. A, Immunofluorescence of SMAD3 activating phosphorylations at ser423/425 as
stimulated by AngII and ET-1, resulting in SMAD3 localization to the nucleus of the myofibroblast. E2 or DPN substantially blocked this. A
representative study of two is shown. B, Phosphoserine 423/425 SMAD3 immunoblot in fibroblasts exposed to AngII or ET-1  E2 or DPN.
Cell lysate was immunoprecipitated with antibody to total SMAD 3, and then blotted after SDS-PAGE separation with phospho-SMAD
antibody. Total SMAD protein is shown as loading control. The bar graph is three experiments combined. *, P  0.05 for AngII or ET-1 vs.
control. , P  0.05 for hypertrophic factors vs. same plus E or DPN. C, JNK activity modulation. Fibroblasts were incubated with hypertrophic
agents  E2 or DPN for 1 or 16 h, and the JNK protein was immunoprecipitated and then used for in vitro kinase activity against exogenous c-jun
protein as substrate. Total JNK-1 protein serves as normalization control. The bar graph is three experiments combined. P  0.05 for AngII, ET-1,
or TGF- vs. control. , P  0.05 for hypertrophic factors vs. same plus E or DPN. D (top), siRNA knockdown of JNK1 or JNK2 protein shown by
immunoblot at 48 h after transfection. D (bottom), Fibronectin and collagen protein are altered by JNK siRNAs. Cardiac fibroblasts were
transfected with control siRNA (control), or JNK1 or JNK2 siRNAs, recovered for 24 h, and then incubated with AngII or TGF1 for 24 h. Actin
protein serves as loading control. E, JNK signals to SMAD3 phosphorylation. Cells were transfected with JNK1 or JNK2 siRNAs, recovered, and then
incubated with TGF1 or AngII. Data analysis of three combined studies was carried out as noted in Fig. 1D. F, Quantitative PCR of collagens I and
III gene expression in cardiac fibroblasts. Cells were incubated with AngII or TGF1 for 24 h, RNA was then extracted, and quantitative PCR was
carried out as described in Materials and Methods. In all cells, control or SMAD3 siRNA was transfected 24 h before hypertrophic factor
incubation. The study was carried out three times for data analysis. *, P  0.05 for control siRNA vs. same plus AngII or TGF1. , P  0.05 for
AngII or TGF1  control siRNA vs. AngII or TGF1  SMAD3 siRNA. G, Myofibroblast formation is mediated by JNK. Fibroblasts were incubated
with JNK1 or Jnk2 siRNAs, recovered, and then incubated with AngII or ET-1 for 24 h. Myofibroblasts were then counted. Bar graph is from three
experiments, mean  SEM. *, P  0.05 for control vs. AngII or ET-1; , P  0.05 for AngII or ET-1 vs. same  JNK siRNA.
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by E2 or DPN. To confirm this, we carried out Western
blots of serine423/425 phospho-SMAD3 from whole
cells exposed to AngII or ET-1  E2 or DPN. The more
than 2-fold stimulation of p-SMAD by the hypertrophic
agents was significantly and comparably prevented by E2
or DPN, implicating ER (Fig. 3B).
Fibrosis-inducing signal transduction is inhibited
by E2/ER
As a second possible regulatory signal, TGF1 stimu-
lates collagen and fibronectin production through a c-jun
N-terminal kinase (JNK) pathway (34, 35). We first de-
termined that AngII, ET-1, and TGF1 each stimulated
FIG. 3. (Continued).
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JNK activity at 1 and 16 h, significantly inhibited by E2 or
DPN (Fig. 3C). To determine whether JNK is required for
the fibrosis-inducing effects of the hypertrophic agents,
we took an RNA interference approach. Specific siRNA
to JNK1 or JNK2 each knocked down only the intended
target protein at 48 h (Fig. 3D, top). We then determined
whether proteins indicative of the fibroblast transition
and subsequent production of fibrosis were modulated by
the loss of JNK signaling. We found that the JNK 1 and 2
isoforms strongly contributed to the ability of AngII or
TGF to stimulate fibronectin (indicating myofibroblast
transition) or to increase collagens (promoting fibrosis)
(Fig. 3D, bottom). This correlated to the proportional
ability of each JNK siRNA to knock down the target
protein expression.
TGF stimulates SMAD nuclear translocation and
function onDNA in fibroblasts, in part through JNK, and
JNK is therefore upstream to fibroblast protein produc-
tion (35). To link JNK to SMAD in our model, we deter-
mined that AngII or TGF-induced SMAD3 phosphoryla-
tion in the cardiac fibroblastswas substantially preventedby
JNK-1 or JNK-2 siRNA (Fig. 3E). We also investigated the
FIG. 4. E2 signals to the inhibition of fibrosis. A, E2 or DPN stimulates cAMP generation in cardiac fibroblasts. Fibroblasts were incubated with 10
nM E2 or DPN  AngII or ET-1, and cAMP was measured after 5-min incubation. Mean  SEM data are from three studies combined with duplicate
determinations per condition in each experiment. *, P  0.05 for control or AngII or ET-1 vs. E2 or DPN or E2/DPN plus hypertrophic factor. B,
ER, but not ER, mediates the ability of estrogenic compounds to stimulate cAMP. Fibroblasts were first transfected with siRNA to ER, ER, or
GPR30, and the cells were recovered overnight and then incubated with E2 for 5 min. Bar graph is from three experiments; *, P  0.05 for control
vs. E2 or DPN or vs. E2 or DPN with ER or GPR30 siRNA. , P  0.05 for E2 or DPN vs. same  ER siRNA. C, Dependence on Gs coupling to
ER for cAMP generation by E2. Fibroblasts were transfected with dominant-negative C-terminal minigenes for Gs and Gi, and the cells were
recovered and then exposed to E2, DPN, or PPT. Bar graph is from three experiments; *, P  0.05 for control vs. E2 or DPN  Gi construct.
, P  0.05 for E2 or DPN vs. same  Gs construct. D, Inhibition of cAMP or PKA reverses the E2-induced block of myofibroblast development.
Fibroblast to myofibroblast differentiation in response to AngII or ET-1 was inhibited by E2, but the E2 effect was prevented by 5 nM H-89 (PKA
inhibitor) or 10 M Rp-8-Br-cAMP (cAMP inhibitor). Cells were exposed to peptide  steroid for 24 h, in the absence or presence of cAMP or PKA
inhibitor. The bar graph is from three experiments combined. *, P 0/05 for control (lane 1) vs. AngII or ET-1; , P  0.05 for AngII or ET-1 vs.
same  E2; , P  0.05 for AngII or ET-1  E2 vs. same  Rp-8-Br-cAMP or H-89. E, cAMP cross talks to inhibit JNK activation. Cells were
incubated with TGF1 or AngII  E2 with or without Rp-8-Br-cAMP for 10 min, and then JNK activity was determined as described. The study was
done two times and the data were combined.
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importance of SMAD3 for fibrosis here by examining its
role in the modulation of collagens I and III gene(s) tran-
scription as determined by quantitative PCR. AngII and
TGF1 each stimulated significant increases in the ex-
pression of genes encoding both collagens, compared
with control, but this was substantially reduced by
SMAD3 siRNA (Fig. 3F). JNK also significantly contrib-
uted to the ability of AngII and Et-1 to stimulate myofi-
broblast formation (Fig. 3G). In summary, hypertrophic/
fibrosis-inducing peptides significantly stimulated
SMAD3 phosphorylation and nuclear localization and
myofibroblast formation via JNK signaling, the former
inhibited by E2 and DPN. As a result, enhanced collagen
production was prevented by the ER ligands.
Rapid signaling by E2/ER inhibits fibrosis
How does E2/ER signal to inhibit the key features of
hypertrophic factor action in fibroblasts? Overexpression
and activation of adenylyl cyclase blocks fibroblast to
myofibroblast transition (36), suggesting that cAMP gen-
eration may play an important role in the actions of E2.
Additionally, some evidence suggests that downstream of
cAMP, protein kinase A (PKA) may mediate the effects of
cAMP (36).
To determine whether this is a potential mechanism,
cardiac fibroblasts were incubated with E2 or DPN 
ET-1 orAngII for 5min and cAMPwasmeasured. As seen
in Fig. 4A, both E2 and DPN significantly stimulated
cyclic nucleotide production, modestly affected by AngII
or ET-1 whereas the latter two proteins had no effect. We
also determined that stimulation of cAMP in response to
E2 or DPN was unaffected by siRNA to ER but was
significantly compromised by knockdown of ER (Fig.
4B). In contrast, no effect of GPR30 knockdownwas seen
for the ability of E2 or DPN to generate cAMP. Our
results are consistent with observations that E2 rapidly
stimulates cAMP in other cells (29) and may be a mecha-
nism of E2/ER action here. The rapidity of E2 or DPN
action suggests that cAMP is generated throughmembrane-
localized ER in fibroblasts (Fig. 1B) and is consistent with
E2 generating functional and rapid kinase activation in our
hypertrophic myocyte models (20).
Adenylyl cyclase is activated upon stimulation of Gs
by many G protein-coupled receptors at the plasmamem-
brane (37). To support themechanism bywhich only ER
generates cAMP,we expressed a dominant-negative (DN)
Gs C-terminal minigene in the fibroblasts (38). As a
specificity control, we also expressed a Gi minigene; Gi
has been shown to have a modest inhibitory effect on
cAMP (39), and we previously used these constructs (40).
Brief exposure of the cells to E2 or DPN generated in-
creased cyclic nucleotide, and this was significantly al-
though partially prevented by only the Gs dominant-
negative protein (Fig. 4C). PPT did not stimulate cAMP
in these cells, and the Gi DN protein produced an
insignificant augmentation of cAMP generation both in
basal and E2-treated cells, consistent with the mild in-
hibitory effect of this small G protein on cAMP gener-
ation (39). Thus ER is selectively linked to Gs-me-
diated cAMP generation.
We then determined that inhibitors of cAMP RP-8-
bromo cyclic adenosine monophosphate (RP-8-Br-
cAMP) and PKA (H-89) reversed the ability of E2 to
inhibit myofibroblast transition (Fig. 4D, lanes 2–9),
whereas the inhibitors, by themselves, had no effects.
Thus, the cAMP-PKA pathway underlies the effects of
E2/ER in an important manner.
Might E2/ER signaling through cAMP and PKA im-
pact the JNK pathway, potentially indicating a specific
cross-target of E2 action? We found that AngII and
TGF1 stimulation of JNK activity was blocked by E2
but the steroid effect was significantly prevented upon
inhibiting cAMP with Rp-8-Br-cAMP and PKA with
H-89 (Fig. 4E). Thus, a rapid signaling pathway initiated
by liganded ER in fibroblasts (likely at the membrane)
causes cAMP and PKA augmentation. This signaling
blocks AngII and TGF1 stimulation of JNK activity that
leads to SMAD3 phosphorylation and nuclear localiza-
tion and fibronectin and collagen production.
In vivo studies
We then investigated E2 effects inWT and ER knock-
out (KO) mice (41) infused with AngII for 21 d to create
cardiac hypertrophy and fibrosis (13). E2 pellets produced
physiological serum levels in this model, and functional
FIG. 4. (Continued).
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studies as determined by echocardiography were previously
reported (13). Previously, we found that AngII-induced car-
diac hypertrophy was significantly inhibited by E2 inWT
and ERKOmice but not in ERKOmice. AngII-induced
muscle shortening and enhanced contraction, as seen by
echocardiography, were significantly prevented by the
sex steroid (13).
We first corroborated here that AngII induced hy-
pertrophy and E2 prevented this by approximately
60% in WT but not ERKO mice (Fig. 5A). This was
particularly evident for the left ventricle (Fig. 5B). We
then assessed fibrosis and found that AngII infusion
caused a 7-fold increase in fibrosis relative to saline
infusion (control) (Fig. 5C). E2 significantly inhibited
fibrosis by more than 80% but only in WT mice (Fig.
5C). Key protein(s) expression in whole ventricle (not
just fibroblasts) was determined by immunoblot. All
proteins were significantly increased in AngII-infused
WT or ERKO mice, compared with
saline-infused (control) mice. E2 sig-
nificantly inhibited the expression of
collagens I and III, TGF1, vimentin,
and fibronectin in WT but not
ERKO mice (Fig. 5D). These results
support the findings from isolated fi-
broblasts and suggest potential appli-
cation in vivo.
Discussion
Fibrosis is an important and debilitat-
ing development in the progression of
cardiac hypertrophy (22, 23). This pro-
cess occurs in both the interstitial and
perivascular spaces of the myocardium
and is a prime cause of diastolic stiffness,
contractility dysfunction, and progres-
sion to ventricular wall thinning and
heart failure. Here we show that E2 act-
ing at ER rapidly signals through
cAMP and PKA to directly preventmyo-
fibroblast development and the produc-
tion of collagen, vimentin, and fibronec-
tin proteins that remodel tissues. We
report this also occurs during in vivo hy-
pertrophy induced by AngII where E2
prevents fibrosis in ovariectomized WT
but not ER KOmice.
The participants involved in fibrosis
are multiple and interactive. AngII and
ET-1 up-regulate TGF1 production in
the fibroblast, the latter protein subse-
quently inducing the phosphorylation of SMAD3 by sig-
naling from the autocrine TGF receptor. Phosphoryla-
tion of the SMAD transcription factor correlated to
nuclear translocation (Fig. 3) where SMAD promoted
collagen gene transcription.We implicate Jnk1 and Jnk2
signaling in these critical events, and TGF-induced
JNK has also been reported to promote SMAD binding
to DNA in some cells (34). We importantly find that E2
or DPN blocks the phosphorylation of SMAD3 through
stimulating cAMP and PKA production that inhibits
JNK activity. cAMP is generated by ER specifically
coupling to Gs activation and cAMP, and PKA inhi-
bition of JNK activation provides a novel mechanism
for previous observations that cAMP inhibits TGF-
induced SMAD signaling to collagen production (36,
42, 43). In addition, we found that cAMP/PKA cont-
ributes to E2-inhibition of the fibroblast transition. A
FIG. 5. In vivo prevention of cardiac fibrosis by E2. A, Hearts are from ovariectomized female
WT or ERKO mice infused with saline or AngII (in saline)  insertion of E2 pellet for 21 d;
representative specimens are shown. The inset bar on the pictures is 2 mm. Heart-body
weight ratios reflect cardiac hypertrophy and are calculated from five mice per group. *, P 
0.05 for saline vs. AngII or AngII  E2 in ERKO mice. , P  0.05 for AngII vs. same  E2 in
WT mice. B, Left ventricular hypertrophy in the same types and numbers of mice, under the
same conditions. The left ventricle of each heart was dissected free and then weighed (LVW),
and a ratio was created to body weight (BW). Representative additional transverse sectioned
hearts are shown (RV, right ventricle; LV, left ventricle). *, P  0.05 for saline vs. AngII or
AngII  E2 in ERKO mice. , P  0.05 for AngII vs. same  E2 in WT mice. C, Cardiac
fibrosis in the left ventricle of ovariectomized female mice. The area of fibrosis was scored as
described in Materials and Methods. Bar graph is data from five mice per condition. D,
Protein expression in the left ventricles of the same mice exposed to the various experimental
conditions. Bar graph data were derived from the densitometry of the protein immunoblots,
normalized for total protein in the samples and for -actin expression.
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cartoon showing these pathways is seen in Fig. 6. EGF
and PDGF also have been implicated in hypertrophy and
the associated fibroblast transition to myofibroblasts (30,
31). We establish here that EGF and PDGF directly act at
the fibroblast and provide evidence that E2/ER also
blocks the myofibroblast-promoting actions of these
growth factors.
Additional pathways have been proposed for the pro-
duction of myocardial fibrosis. ET-1 and AngII-induced
TGF1 stimulates connective tissue growth factor
(CTGF). CTGF increases matrixmetalloproteinase 2 pro-
duction via SMAD2 and stimulates fibroblast to myofi-
broblast conversion (24, 44). Additionally, AngII stimu-
lates activation of the small G protein Rho A, leading to
Rho kinase activation (45) andmyofibril formation in the
heart (46). Inhibition of Rho kinase activity or specific
deletion of cardiomyocyte Rho kinase type 1 inmice leads
to decreased fibrosis in several hypertrophy models (46,
47). Rho kinase causes the stimulation of TGF1 and
CTGF production, implicating Rho as upstream to
TGF1 but downstream of AngII (45, 48). Interestingly,
we find that AngII and ET-1 strongly stimulate Rho ki-
nase activity in the fibroblasts, and E2 and DPN signifi-
cantly inhibit kinase activation (our unpublished data).
Our results implicate a novel func-
tion for ER. This probably results
from the rapid signaling that occurs
when E2 binds to the membrane-local-
ized pool of this sex steroid receptor.
We demonstrate here the existence of
this endogenous subcellular pool in the
isolated cardiac fibroblast/myofibro-
blast and previously showed that it is
membrane-localized (and not nuclear-
localized) ER that is responsible for
rapid signaling (49). Also, Gs and ad-
enylyl cyclase are membrane-associ-
ated proteins that interact to stimulate
cAMP generation. E2 engaging ER
rapidly signals to also prevent cardio-
myocyte hypertrophy, in vitro and in
vivo (13, 20). In myocytes, E2/ER in-
hibits AngII-induced protein phospha-
tase 2B (calcineurin) activity by stimu-
lating transcription of the MCIP1 gene
through a phosphatidylinositol-3-ki-
nase mechanism (13, 20). Blocking
calcineurin activation resulted in the re-
tention of the nuclear factor of acti-
vated T-lymphocytes c3 transcription
factor in cytoplasm, thereby preventing
hypertrophic gene transcription. E2/
ER also promoted the transcription
and resulting autocrine functions of atrial and brain na-
triuretic peptides in cardiomyocytes to blockAngII hyper-
trophic signaling through ERK MAPK (13, 20). In vivo,
E2 acted equivalently in WT and ER KO female mice in
these respects but had no effects in ER KO mice (13).
These data collectively support the idea that adminis-
tering a selective ER agonist may prevent the develop-
ment of cardiac hypertrophy (17) and fibrosis (present
paper). Such an agonist may also lower blood pressure
(11, 17). This could be useful, for instance, in hyperten-
sive women whose blood pressure is not well controlled
and are therefore at risk for developing cardiac hypertro-
phy and fibrosis. The advantage of using an ER agonist
instead of E2 is that the ER agonist would avoid the
proliferative effects of E2 on the uterus and breast that
contribute to hormone-related cancers.
Extending the breadth of our findings here, we pro-
pose that the ability of E2/ER to prevent fibrosis is not
confined to the heart. Supporting this idea, the ERKO
mouse has a prominent phenotype of pulmonary fibro-
sis (41). In decompensated hypertensive heart disease,
pulmonary fibrosis can occur, and perhaps E2/ER can
prevent this. Furthermore, chronic hepatitis infection
FIG. 5. (Continued).
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(50) or hepatotoxins (51) induce inflammatory changes
in the liver resulting in progressive hepatic fibrosis,
cirrhosis, and hepatocellular carcinoma. Premeno-
pausal women or female rats are relatively protected
from these events due to estrogen action, and some data
support a role for ER (50). The mechanisms of E2
preventing hepatic or lung fibrosis are not well under-
stood. Investigation of the utility of ER agonists might
provide mechanistic insight and prevent fibrosis in
other organs.
In summary, estrogen acts through ER produced in
both the cardiomyocyte and cardiac fibroblast to prevent
key elements of progressive heart disease, in vitro and in
vivo. We believe these studies justify further preclinical
and early translational trials using ER-specific agonists
in women (and perhaps men) at risk for developing pro-
gressive cardiac hypertrophy and fibrosis.
Materials and Methods
Reagents
Peptides AngII (Sigma Chemical Co., St. Louis, MO), ET-1
(AnaSpec, Inc., Fremont, CA), EGF, PDGF, and TGF1 (R&D
Systems, Minneapolis, MN), or steroids E2
(Steraloids Inc., Newport, RI), PPT, and
DPN (Tocris Bioscience, Ellisville, MO)
were purchased from the designated com-
panies. Antibodies to ER (C terminus)
(Santa Cruz Biotechnology, Inc., Santa
Cruz, CA) and ER (C terminus) (Invitro-
gen, Carlsbad, CA) were used for immu-
noblots of subcellular fractions as described
(29). Antibodies for immunofluorescent
microscopy included -SMA (Santa Cruz)
and phospho-SMAD3 (Abcam Inc., Cam-
bridge, MA). Additional antibodies for
immunoblots included TGF1 (Abcam),
fibronectin (Santa Cruz), and vimentin
(Santa Cruz), collagens I and III, JNK 1
and 2, and -smooth muscle actin (Santa
Cruz). siRNAs to JNK1 and JNK2,
SMAD 3, GPR30, and ER and ERwere
from Santa Cruz. Rp-8-Br-cAMP and
H89 were from Calbiochem (La Jolla,
CA) and ICI 182780 was from Sigma.
In vitro studies
Primary culture of cardiac fibroblasts
Cardiac fibroblast cells were isolated
from the hearts of 2-d-old neonatal Sprague
Dawley rats (The Jackson Laboratory, Bar
Harbor, ME). Briefly, ventricles were re-
moved under sterile conditions, placed in
cold sterile Hank’s buffered saline, minced
into approximately 2-mm cubes, then
treated with 1 mg/ml collagenase (type II;
Worthington Biochemical Corp., Lake-
wood, NJ) under agitation at 37 C for 30
min. The supernatant was discarded, and the tissue pellet was
resuspended and agitated in 0.025% trypsin (Life Technologies,
Inc., Gaithersburg, MD) in Hank’s buffered saline for 10-min
intervals until the tissue was completely dispersed. Cells were
then pelleted by centrifugation. Dissociated cells were passed
through a 100-m mesh strainer and preplated for 45 min in
DMEM (Sigma) containing 10% heat-inactivated fetal bovine
serum (FBS) (Hyclone Laboratories, Logan, UT). This process
was repeated twice, and cells were collected after trypsin treat-
ment (to allow preferential attachment of the myocytes, while
the fibroblasts are in suspension). The resulting cardiac fibro-
blasts were pelleted, then resuspended in DMEM containing
10% FBS, 100 U/ml penicillin, and 100 g/ml streptomycin
(Life Technologies) and seeded in standard culture dishes. All
fibroblasts used in the experiments were at passage 2. Some
cells were cultured on poly-D-lysine coated, 35-mm glass-
bottom dishes (MatTek Corp., Ashland, MA) for cell local-
ization of proteins by fluorescent microscopy. For functional
studies, fibroblasts were cultured in six-well plates and ex-
posed to AngII or ET-1 (100 nM), PDGF (10 nM), EGF (100
nM)  10 nM E2, PPT, or DPN. In some experiments, cells
were exposed to 10 nM TGF1 for 1 or 16 h. siRNAs were
transfected and used for experiments after 24–48 h when
cells reached approximately 75% cell confluency. Myofibro-
blasts were identified after the fibroblasts were incubated
with AngII or ET-1 (100 nM)  10 nM E2 or DPN for 24 h by
FIG. 6. Cartoon showing the pathway of cardiac fibrosis inhibited by E2/ER. ET-1 and AngII
stimulate TGF1 production in fibroblasts, inducing myofibroblast formation, SMAD
phosphorylation via JNK activation, and SMAD trafficking to the nucleus. Nuclear SMAD is
required for collagen gene up-regulation and enhanced protein production as well as other
vital protein(s) production, leading to fibrosis. E2/ER inhibits these events via cAMP/PKA
signaling to block ET-1- and AngII-induced myofibroblast formation and JNK activation by TGF1.
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immunohistochemical staining for -SMA, and by general
morphology. In each experiment, the fibroblast to myofibro-
blast ratio in each condition was determined by counting 200
cells.
cAMP and JNK kinase determinations
cAMP was measured in fibroblasts using a kit (PerkinElmer,
Boston,MA) as previously described (29) after 5min incubation
of the cells with E2 or DPN  AngII or ET-1. In additional
studies, C-terminal Gs or Gi plasmids (Cue Biotech, Chicago,
IL) (37) that serve as dominant negatives to the endogenous
small G proteins were transfected into the fibroblasts, the cells
recovered overnight and then exposed to E2, PPT, or DPN for 5
min. cAMPwas then measured. For JNK activity, cardiac fibro-
blast cells were cultured and then treated with various experi-
mental conditions for 10 min. Cells were lysed at that time in
buffer [50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 100 mM NaCl,
50 mM NaF, 100 M phenylmethylsulfonyl fluoride, protease
inhibitor cocktail, and 0.2% Triton X-100]. Cell lysate from
each condition was exposed to Protein A/G agarose to ensure
removal of endogenous IgG in a microcentrifuge tube contain-
ing 50 l of the suspended agarose beads, for 30 min at 4 C
while rotating. The cell lysate-protein A/G bead complex was
centrifuged at maximum speed on a desktop centrifuge for 30
sec at 4 C. Without disturbing the pellet, the supernatant was
transferred to a new tube. The precleared supernatants were
stored on ice. For the JNK activity assay, 10 l of JNK antibody
were conjugated to 50 ml of protein A/G beads for 2 h at room
temperature and washed. Then, 1 ml of precleared whole-cell
extract was added to JNK antibody/protein A/G bead complex,
and rotated end-over-end overnight at 4 C. Beads were washed
once with lysis buffer and twice with HEPES buffer (25 mM
HEPES, 10mMMg-acetate). To the lysates-antibody-bead com-
plexes, we added 40 l of a mixture, containing 20 ml of 3
kinase buffer (25 mM HEPES, pH 7.5; 10 mM MgAc, 2 mM
dithiothreitol; 40 mM ATP), and 10 ml of H20, to 2 mg c-Jun
protein in 9 ml of water, and 1 l -32P-ATP. Each tube was
vortexed and incubated at 30 C for 30 min. SDS-PAGE loading
buffer (40 l) was then added, vortexed, boiled for 5 min, and
centrifuged at 14,000 rpm for 1 min. Forty microliters per con-
dition sample were loaded onto a 10% gel. After electrophore-
sis, the gel was fixed, dried, and subjected to autoradiography.
[35S]methionine metabolic labeling of cells
Cells were cultured in 60-mm dishes and were 90% conflu-
ent at the time of experiment. To pulse the cells with [35S]me-
thionine, normal culture medium was removed and 2 ml methi-
onine-free DMEM, supplemented with 10% dialyzed FBS, were
added into each dish followed by addition of 20 l (250 Ci) of
[35S] methionine/cysteine/well (PerkinElmer). After 2 h of puls-
ing, 35S-containing medium was removed, and normal culture
medium was added back, with or without stimulants for the
indicated times. Cells were then lysed with 1 ml lysis buffer.
After a complete set of samples was collected, lysates were spun
at 12,000  g for 10 min at 4 C, and clear supernatant was
collected. For immunoprecipitation, 10 l anticollagen I or col-
lagen III antibodies were added to 30 l protein A/G Plus-aga-
rose (Sigma) and rotated at room temperature for 2 h. After
washing four times with lysis buffer, lysates were added to
antibody-bead complex and rotated at 4 C overnight. Samples
were washed with cold PBS and then were heated at 95 C for 5
min in loading buffer [50 mmol/liter Tris (pH 6.8), 2% sodium
dodecyl sulfate, 10% glycerol, 100 mmol/liter dithiothreitol]
and separated on a 12% SDS-PAGE gel. Gels were dried and
exposed to x-ray film followed by densitometry analysis. Addi-
tionally, immunoblots for TGF1, -SMA, vimentin, and fi-
bronectin proteins were determined as previously described (13,
20). Briefly, cardiac fibroblasts were exposed to hypertrophic
peptides steroids for 24 h; the cells were lysed, and individual
proteins were immunoprecipitated, reduced, and separated by
SDS-PAGE on a gel before transfer to nitrocellulose. Transfer
was followed by immunoblotting.
Gene expression by quantitative real-time PCR
Total RNA was extracted using the RNeasy Mini Kit
(QIAGEN, Chatsworth, CA) following the manufacturer’s pro-
tocol. All the samples were treated with DNAse-free trizol re-
agent (Ambion, Inc., Austin, TX). RNA purity and concentra-
tions were measured by UV-spectrophotometry (A260 and
A280). cDNAwas synthesized using approximately 500 ngRNA
and Oligo dT primers with the Improm-II reverse transcription
system (Promega Corp., Madison, WI). Quantitative real time
PCR (qRT-PCR) was used to examine the relative expression of
collagen I and collagen III. Expression was normalized using the
housekeeper GAPDH gene. Primers were designed using Prim-
er3 (http://frodo.wi.mit.edu/). Blast analysis was used to check
specificity [primers: collagen I forward (F) (5-tgctgccttttctgttc-
ctt-3); collagen I reverse (R) (5-aaggtgctgggtagggaagt-3); col-
lagen IIIF (5-gtccacgaggtgacaaaggt-3); collagen IIIR (5-
catcttttccaggaggtcca-3); GAPDHF (5-ccacagtccatgccatca-3);
GAPDHR (5-ggatgaccttgcccacag-3)]. Primers were designed
to have an annealing temperature of 55 C and to amplify regions
of 150–200 bp. PCR amplicon sizes were confirmed by agarose
gel electrophoresis before qRT-PCR analysis. For qRT-PCR
analysis, cDNA was combined in a 50-l reaction with 25 l of
SYBR GreenER qPCR Supermix (Invitrogen), 1 l of 10 M
forward/reverse primer stocks, and nuclease-free water. Ther-
mocycling was carried out using the iCycler (Bio-Rad Labora-
tories, Hercules, CA) with a melting curve temperature of 60 C.
Relative mRNA levels were calculated using the Ct method.
Data were normalized to the control siRNA condition.
Mice models
All mouse studies were approved by the Animal Use and
Research and Development Committees at the Long Beach Vet-
erans AdministrationMedical Center and the University of Cal-
ifornia, Irvine. Ovariectomized female wild-type (WT) or ER
gene-deleted mice were obtained from Dennis Lubahn (Univer-
sity of Missouri) (13). The ERmice were originally created by
Gustafsson et al. (49), and control mice were WT littermates.
Mice were housed in 12-h light, 12-h dark lighting and fed
rodent chow devoid of soy or most plant products. AngII (1.1
mg/kg/d) in saline or saline alone-filled osmotic minipumps (Al-
zet; DURECT Corp., Cupertino, CA.) provided 21-d infusion
after sc insertion under inhaled isofluorane anesthesia. In some
mice, an E2 pellet (0.1 mg, 21-d release pellets; Innovative Re-
search of America, Sarasota, FL) or placebo pellet was also
inserted under the skin. This pellet is well documented to pro-
duce physiological levels of E2 in the serum of mice (13, 51). At
inception and after 21 d, the mice were weighed. At 21 d, the
hearts were arrested in diastole by injection of CdCl2 (0.1 mol/
liter iv), followed by cervical dislocation. The hearts were re-
moved and weighed, and the ratio of heart to total body weight
was determined. The left ventricle was also dissected free and
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weighed. Estrogen loss or administration did not significantly
affect body weight over the 3-wk period of the study, and heart
weight was normalized to initial body weight.
Cardiac fibrosis
Hearts and heart sections (left ventricular tissue) were
weighed and then processed by fixing in 3.75% paraformalde-
hyde solution for embedding, or frozen for protein analysis.
Paraffin-embedded tissue sections (5 m) were stained with he-
matoxylin and eosin or Masson’s trichrome, the latter for the
presence of interstitial collagen fiber accumulation indicative of
fibrosis. The ratio of interstitial fibrosis to the total left ventric-
ular area was calculated from 10 randomly selectedmicroscopic
fields from each of five sections per heart using NIH image J anal-
ysis software (n 5 mice per condition). Frozen tissues were used
for relative protein expression, and immunoblots were carried out
on protein extracted from the left ventricle of mice from all condi-
tions, following separation by SDS-PAGE and transfer to nitrocel-
lulose, as we described previously (13, 20).
Statistics
Data were compared by two-way ANOVA plus Schefe’s test
for significant differences between conditions. Statistical signif-
icance of difference was at the 0.05 level.
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